Antibodies targeting amyloid-β and Tau oligomers in Alzheimer's disease.

Alzheimer's disease is a leading neurodegenerative disorder, is characterized by cognitive decline linked to amyloid-beta plaques and Tau tangles. These pathological aggregates disrupt the neuronal communication, induce neuroinflammation, and contribute to synaptic dysfunction. Genetic mutations, aging, environmental and lifestyle factors exacerbate these mechanisms, promoting neurotoxicity. Advances in immunotherapy have targeted Aβ and Tau oligomers using several monoclonal antibodies and Tau-specific antibodies. These therapies aim to neutralize toxic aggregates, facilitate clearance, and slow cognitive decline. Dual-targeting approaches, such as bispecific antibodies, address both Aβ and Tau, enhancing therapeutic efficacy. Despite challenges-like limited blood-brain barrier penetration, off-target effects, and high production costs, innovations in nanobody technology and personalized medicine are the key players. Artificial intelligence-driven antibody design further accelerates development, offering hope for transformative Alzheimer's disease treatments. Future research focuses on optimizing safety and efficacy, paving the way for comprehensive management of this devastating disease.